Whalesbook
Elara Capital ka Sagility par pehla verdict!
Elara Capital ne healthcare tech company Sagility par coverage shuru kar di hai aur 'Buy' rating di hai, saath mein price target ₹54 set kiya hai. Matlab, agar stock yahan se chala toh lagbhag 26% ka faayda ho sakta hai! Iska main reason yeh hai ki jo bade healthcare payers hain na, un par costs badh rahi hain aur Medical Loss Ratios (MLRs) bhi upar ja rahe hain. Is wajah se woh log outsourcing aur zyada services chahte hain, aur Sagility iske liye perfectly positioned hai kyunki unke clients ke saath 18 saal ka average relationship hai.
Healthcare Costs ka pressure aur Sagility ka chance
Healthcare payers ko operating expenses aur MLRs badhne se kaafi dikkat ho rahi hai. Iska seedha fayda Sagility jaise companies ko hoga jo outsourcing services deti hain. United Healthcare, Humana, aur CVS Aetna jaise bade payers bhi is pressure ko feel kar rahe hain, jo Sagility ke liye ekdum sahi mahaul bana raha hai. Company ne FY26 mein 22.5% revenue growth ka target bhi rakha hai.
Growth aur Profit ka outlook
Elara Capital ko lagta hai ki Sagility apne top clients se revenue ko 80-90% tak badha sakti hai. Overall, woh FY26 se FY28 tak revenue mein 13.9% aur earnings mein 20.0% ki CAGR (Compound Annual Growth Rate) expect kar rahe hain. Ha, FY26 mein Broadpath ko integrate karne se margins par thoda pressure aa sakta hai (lagbhag 150 basis points tak EBITDA margins kam ho sakte hain), par FY28 tak woh wapas 25% ke aas paas aa jayenge. FY27 mein debt repayment ke baad finance costs bhi kam ho jayenge, jisse earnings aur accelerate hongi.
Industry ka scene aur valuation
Healthcare IT outsourcing market tezi se grow kar raha hai. Sagility is market mein EXL Service aur WNS Global Services jaise players ke saath compete karti hai. Elara Capital ke mutabik, Sagility ka valuation (FY28E EPS par 15.2x) peers ke muqable sasta lag raha hai, despite kuch analysts ne valuation ya technicals ke karan 'Hold' rating di ho. Motilal Oswal ka target ₹66 aur Jefferies ka ₹64 hai, jo dikhata hai ki sabke views alag hain.
Kya hain risks?
Sabse bada risk client concentration hai, kyunki revenue ka 60% se 85% top 3, 5 ya 10 clients se aata hai. Agar koi bada client chala gaya toh mushkil ho sakti hai. US healthcare regulations mein changes aur generative AI ka future mein kya impact hoga, woh bhi dekhna padega. Company ka ROE aur ROCE industry averages se thoda kam hai, aur promoter holding bhi ghata hai, par debt kam ho raha hai.